
Inflation Is Ticking Upwards. Should Opendoor Investors Be Worried?
Opendoor Technologies has a challenging business model and, on top of that, has executed it poorly.
Higher inflation may keep rates elevated, which would work against Opendoor.
The company's CEO recently resigned, another flashing warning sign.
10 stocks we like better than Opendoor Technologies ›
Prices of various goods and services continue to rise across the U.S. economy.
Currently, the trailing 12-month inflation rate is 2.7% as of July 2025. Research by The Motley Fool tracks inflation, as well as its historical effect on the stock market and consumers. Generally speaking, too much inflation isn't a good thing.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
One area of the economy where inflation can have an effect is real estate. Opendoor Technologies (NASDAQ: OPEN) is trying to revolutionize the housing industry with an e-commerce business model, but the company has struggled. Should investors worry about inflation ticking upwards, and how that could affect Opendoor and the housing market?
The root of Opendoor's struggles
Opendoor is trying to build an Amazon -like e-commerce model for the housing industry, where people can buy and sell homes online. The company buys homes, usually those in good condition or those that only need minor repairs, then resells them on its online marketplace. It sounds like a great idea, but the company hasn't been able to turn that into a sustainable business yet.
The profit margins are slim. Opendoor has to balance competitive offers for homes it buys with the need to resell those properties at a profitable price. Opendoor acquires homes with debt so that it can operate at a larger scale, but debt incurs interest expenses.
Therefore, the company's goal is high inventory turnover, quickly buying and reselling homes to spread the cost of its capital and business operations across as many transactions as possible. All of this is even harder when you consider that market conditions and interest rates can change. Rapid interest rate hikes caught Opendoor off guard a few years ago and incurred massive losses on the inventory it was stuck holding on to.
To put it kindly, Opendoor Technologies has not been a good investment thus far. The company went public via a SPAC merger in late 2020, and the stock has dropped over 90% from its all-time high.
What happens if inflation heats up, and how might that affect Opendoor?
The housing market is slow right now, and that's working against Opendoor.
High interest rates on mortgages are the primary culprit. Rates on 30-year mortgages are currently at 6.5%. Higher rates can make housing payments dramatically more expensive. For example, suppose you buy a home for $420,000 using a 5% down payment and a conventional 30-year mortgage. The difference in the monthly payment on a mortgage with a 5% rate versus a 7% rate is over $500.
The Federal Reserve (the Fed) controls the federal funds rate, the economy's benchmark rate at which banks lend to each other. It doesn't solely determine mortgage rates, but it does influence them. If inflation continues to rise, the Fed may be reluctant to lower rates or could even raise them to cool inflation down.
It would be hard to see the housing market loosening up in that scenario, which would continue to make things difficult for Opendoor.
Should investors worry about Opendoor, or is the stock a buy?
Opendoor Technologies recently soared over 500% after a hedge fund manager posted about the stock on social media. Since then, the stock has cooled off some, but remains highly volatile. Adding to the uncertainty is the recent resignation of CEO Carrie Wheeler, who announced that she was stepping down from her position following the company's most recent earnings report.
So, where does that leave investors right now? For one thing, if inflation continues to rise, Opendoor and its investors should be concerned. Second, it would work against Opendoor if the Fed maintains a high federal funds rate. Beyond that, an already struggling company now lacks leadership at the helm. Perhaps change will be a good thing, but it's hard to give Opendoor the benefit of the doubt.
Despite the stock's recent rally, it's probably best to avoid Opendoor until there is a new CEO in place and the company shows at least two or three consecutive quarters of improved business performance. For now, it's unclear whether Opendoor can even keep its doors open over the long term.
Should you invest $1,000 in Opendoor Technologies right now?
Before you buy stock in Opendoor Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Opendoor Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!*
Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
2 hours ago
- CTV News
As Whoop-Up Days continues to evolve, so does its impact on the local economy
With Whoop-Up Days in full swing, the local economy is already seeing a boost in spending at the grounds, in restaurants and for travel.


Globe and Mail
2 hours ago
- Globe and Mail
Analysts Offer Insights on Technology Companies: Intuit (INTU) and Roper Technologies (ROP)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Intuit (INTU – Research Report) and Roper Technologies (ROP – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Intuit (INTU) In a report released today, Brent Thill from Jefferies maintained a Buy rating on Intuit, with a price target of $850.00. The company's shares closed last Tuesday at $701.03, close to its 52-week high of $714.78. According to Thill is a 5-star analyst with an average return of 13.2% and a 64.2% success rate. Thill covers the Technology sector, focusing on stocks such as International Business Machines, Palantir Technologies, and Procore Technologies. ;'> Intuit has an analyst consensus of Strong Buy, with a price target consensus of $843.86, implying a 18.0% upside from current levels. In a report issued on August 18, Barclays also maintained a Buy rating on the stock with a $815.00 price target. Roper Technologies (ROP) Citi analyst George Kurosawa initiated coverage with a Buy rating on Roper Technologies yesterday and set a price target of $626.00. The company's shares closed last Tuesday at $532.59. According to Kurosawa is ranked #9177 out of 9989 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Roper Technologies with a $640.23 average price target, implying a 20.3% upside from current levels. In a report issued on August 12, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $616.00 price target.


Globe and Mail
2 hours ago
- Globe and Mail
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. 'I am delighted to welcome Martin Steegmaier to Molecular Partners, where his extensive expertise in oncology, business and leadership will provide further impetus to our efforts to deliver unique cancer therapies,' said Patrick Amstutz, Ph.D., CEO of Molecular Partners. 'Martin's experience will be invaluable in leading the research organization and as we continue to innovate and advance our pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation.' Martin Steegmaier joins Molecular Partners from SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies, including as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology. He previously held various positions in pharma partnering and oncology disease areas at Roche, becoming Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich, and at Boehringer Ingelheim in oncology drug discovery. Martin graduated from the Northern Arizona University and holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. Martin Steegmaier, Ph.D., said: 'I'm pleased to join the exceptional team at Molecular Partners and to contribute to pioneering the cutting-edge DARPin therapeutics. I have built up considerable experience in oncology over my career, including developing large molecules at Roche and other organizations, which is directly relevant to the advancement of Molecular Partners' exciting DARPin platforms and pipeline. I am looking forward to working with the team and to driving forward the next generation of DARPin therapeutics for patients with high unmet need.' About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. Tel: +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.